| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAB6A |
| Uniprot No | P20340 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-208aa |
| 氨基酸序列 | STGGDFGNPLRKFKLVFLGEQSVGKTSLITRFMYDSFDNTYQATIGIDFLSKTMYLEDRTVRLQLWDTAGQERFRSLIPSYIRDSTVAVVVYDITNVNSFQQTTKWIDDVRTERGSDVIIMLVGNKTDLADKRQVSIEEGERKAKELNVMFIETSAKAGYNVKQLFRRVAAALPGMESTQDRSREDMIDIKLEKPQEQPVSEGGCSC |
| 预测分子量 | 30.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于RAB6A重组蛋白的参考文献(示例基于领域内典型研究方向，部分信息为模拟概括)：
1. **文献名称**: *"Functional characterization of recombinant RAB6A in vesicular trafficking"*
**作者**: Goud B. et al.
**摘要**: 研究通过大肠杆菌系统表达并纯化重组RAB6A蛋白，证实其GTPase活性，并利用体外实验证明其调控高尔基体到内质网的囊泡运输，揭示了RAB6A与效应蛋白相互作用的关键结构域。
2. **文献名称**: *"Structural insights into RAB6A activation and effector binding"*
**作者**: Eathiraj S. et al.
**摘要**: 通过X射线晶体学解析重组人源RAB6A的GTP结合状态结构，阐明其构象变化机制，并鉴定出与驱动蛋白KIF20A结合的特定界面，为癌症相关运输异常提供分子基础。
3. **文献名称**: *"RAB6A interacts with the exocyst complex via recombinant protein assays"*
**作者**: Wang T. et al.
**摘要**: 利用重组RAB6A进行蛋白质互作实验，发现其直接结合exocyst复合体亚基Sec15.调控分泌途径中囊泡的锚定与融合过程，提示RAB6A在细胞极性生长中的功能。
**注**：以上为模拟示例，实际文献需通过数据库(如PubMed、Google Scholar)检索关键词“RAB6A recombinant”、“RAB6A purification”或结合具体研究领域筛选。
**Background of RAB6A Recombinant Protein**
RAB6A, a member of the Ras-related RAB GTPase family, plays a central role in regulating intracellular membrane trafficking, particularly within the Golgi apparatus and associated transport pathways. As a small GTP-binding protein, RAB6A cycles between active (GTP-bound) and inactive (GDP-bound) states, acting as a molecular switch to coordinate vesicle formation, motility, and fusion. It is primarily involved in retrograde transport from the Golgi to the endoplasmic reticulum (ER) and intra-Golgi trafficking, though its isoforms (RAB6A and RAB6A’) may also influence anterograde transport or exocytosis under specific contexts.
The recombinant RAB6A protein is produced through heterologous expression systems (e.g., *E. coli* or mammalian cells), enabling precise study of its biochemical and functional properties. Recombinant versions often include tags (e.g., GST, His-tag) for purification and detection, retaining native conformational and enzymatic activities. This engineered protein serves as a critical tool for investigating RAB6A’s interactions with effectors (e.g., BICD, dynactin, RABGAP1) and its role in cellular processes like cytokinesis, autophagy, and cell signaling.
Dysregulation of RAB6A is linked to pathologies, including cancer metastasis, neurodegenerative disorders, and infectious disease mechanisms. Recombinant RAB6A facilitates drug discovery by screening for inhibitors/modulators of its GTPase cycle or binding partners. Its study also aids in deciphering how pathogens (e.g., *Shigella*, viruses) hijack RAB6A-dependent trafficking for intracellular survival. By providing a purified, functional form of the protein, recombinant RAB6A remains indispensable for advancing research into membrane trafficking biology and therapeutic targeting of RAB-mediated pathways.
×
